Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone plus interferon beta-1a for relapsing-remitting multiple sclerosis
ISRCTN68218781Phase 4Completed
- Sponsor
- Biogen
- Start
- Jan 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, double-blind trial in multiple sclerosis (MS) comparing Interferon beta-1a + methylprednisolone with Interferon beta-1a + placebo (2 arms). Primary endpoint: Time to onset of disability progression sustained for at least 6 months. Started Jan 2003; status: completed.
02
Drugs
methylprednisoloneinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN68218781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68218781.